anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an intelligent management and control system of an image target detection device, which relates to the technical field of machine vision and comprises the following components: the disease physiological response database stores physical sign data of various mild diseases during the onset period and corresponding type-B OTC treatment medication information. The image acquisition module is used for collecting sign image data of the detection personnel by using the image target detection device. The pathology learning module is connected with the database, learns through analyzing the sign data and establishes a pathology feature association matrix. The disease analysis module is used for identifying and constructing a mild disease data set of the detection personnel by combining the pathological feature incidence matrix and the collected sign image data. The health evaluation module evaluates the health state of the detection personnel based on the disease data set and formulates a corresponding class B OTC medication management scheme. The system aims to provide rapid, accurate diagnosis and personalized treatment advice for mild disease. The invention has the advantages that: reducing reliance on specialized medical resources and contributing to the health awareness and self-care ability of individuals.
PURPOSE:To easily obtain an extract having high quality and containing the active component of propolis in an easily absorbable and utilizable state on an industrial scale by using a specific purifying process for purifying propolis which is a resinous material stored by honey bees in a nest box. CONSTITUTION:An aqueous solution of a hydrophilic organic solvent (preferably ethanol) having a concentration of 30-55V/V% and containing the active component of propolis is optionally diluted with water and adsorbed to a porous synthetic adsorbent resin (e.g. a porous nonionic styrene-divinylbenzene polymer). The active component of propolis is eluted from the adsorbent resin by using an aqueous solution of a hydrophilic organic solvent having a concentration of preferably >=80V/V% to obtain the objective extract having an absorbance ratio (absorbance at 310nm to absorbance at 660nm) of >=4,000 in terms of a solution having a concentration of 2W/W%. The aqueous solution of a hydrophilic organic solvent having a concentration of 30-55V/V% is produced e.g. by extracting propolis with a hydrophilic organic solvent and diluting the obtained crude propolis extract with water.
Metabolic syndrome (MetS) is a complex hereditary condition comprising various metabolic traits as risk factors. Although the genetics of individual MetS components have been investigated actively through large-scale genome-wide association studies, the conjoint genetic architecture has not been fully elucidated. Here, we performed the largest multivariate genome-wide association study of MetS in Europe (nobserved = 4,947,860) by leveraging genetic correlation between MetS components. We identified 1,307 genetic loci associated with MetS that were enriched primarily in brain tissues. Using transcriptomic data, we identified 11 genes associated strongly with MetS. Our phenome-wide association and Mendelian randomization analyses highlighted associations of MetS with diverse diseases beyond cardiometabolic diseases. Polygenic risk score analysis demonstrated better discrimination of MetS and predictive power in European and East Asian populations. Altogether, our findings will guide future studies aimed at elucidating the genetic architecture of MetS.
Human erythropoietin(I) was produced by implanting human cells capable of producing (I) into any warm-blooded animal other than a human, or by propagating the cells in a device which supplies them with nutrient body fluid directly from warm-blooded animals. The grown cells were then incubated under the reduced O2 condition. Thus, human renal tumor cells and leukemic lymphoblastoid cells were suspended in saline soln. and mixed with inactivated Sendai virus at 37≰C for 1 min. After cloning, the hybridoma cells were implanted in nude mice for 5 wks. and the growing  tumors were extd., minced, suspended in physiol. soln. contg. trypsin and washed with Earle 199 medium contg. 10% calf fetal serum. The cell suspn. was incubated at 370/933 mbar for 20h and sonicated to give 170 unit (I)/ml. (I) is renal cell produced hormone essential to the formation of erythrocytes.
Aerosol compositions, for use as nasal decongestants, comprise polyphloretin phosphate and phenylephrine hydrochloride as active ingredients, together with eucalyptol, and dipropylene glycol, with 1,2 - dichloro - 1,1,2,2 - tetrafluoro-ethane as a propellant.  Other analogues of polyphloretin phosphate may be used (see Divisions A5-A6).ALSO:Nasal decongestive compositions for topical administration comprise a non-toxic carrier with 0.02% to 2.0% by weight of an anti-enzymatic compound having a M.W. of 2,000 to 50,000 which is a condensation product of phosphoric acid with one or more of mono-, di-, or poly-nuclear aromatic compounds containing at least two reactive groups in the meta-or para-position to each other in the same nucleus or di- or polynuclear aromatic compounds containing at least two different reactive groups being -OH, -SH, or -NH3 groups, the linkage to the phosphoric acid groups being through the polyvalent atoms of the reactive groups, the condensation products containing free -OH groups attached to the phosphorus atoms and being water-soluble at alkaline pH.  Particular such compounds are the following phosphates: polyphloretin, polymethylphloretin, polyquercetin, polynaringenin, polyhesperidin, and polyphloroglucinol phosphate. The compositions may take the form of an aqueous solution for use as drops, or a self-propelled aerosol composition (see Div. C4-C5), and may contain other active ingredients such as sympathominetic amines, antibiotics, and antihistamines. Sympathominetic amines used may be phenylephrine, methoxamine, cyclopentadrine, naphazoline, tetrahydrozoline, xylometazoline, hydroxy amphetamine cyclopentamine, mephentermine, methylhexaneamine, and phenylpropyl methyl amine.  Antibiotics specified are amphomycin, bacitracin, erythromycin, chloramphenicol, neomycin, polymixin tetracyclin and tyrothrycin.
The CHD group is made up of the children included in the first study. From these 496 children with CHD, children with a second CPET more than one year from the first referral CPET were included. If several CPETs were performed in the follow-up, we retain the most distant CPET from the first, excluding the CPETs that were performed after a cardiopulmonary rehabilitation program implemented in the region in 2018. The group corresponding to the first CPET was called. Among the initial 496 children, if patients had not had a second CPET, the cause was indicated. As a reminder, the patients included in the initial study were aged 5-18 years old and they were referred by their paediatric cardiologists to one of the two CPET laboratories after their annual medical check-up. The anatomical and clinical classification of congenital heart diseases was used to define the type of malformation. The demographic, clinical, echocardiographic data were collected during the first CPET.
PURPOSE:To obtain a stable phospholipid emulsion in a high concentration, having a low viscosity, good fluidity and useful for fluid therapy, by removing a neutral lipid of natural lecithin to give an aqueous dispersion of purified phospholipid, adding a fat or oil and protein to the dispersion and homogenizing the resultant blend. CONSTITUTION:A neutral lipid is removed from natural lecithin by treatment with cold acetone, etc., to give purified lecithin containing >=20wt% phosphatidyl choline (hereinafter abbreviated to PC). The resultant purified phospholipid is preferably dispersed in hot water at >=80 deg.C to afford a 10-50wt% aqueous dispersion. 20-100wt% fat or oil, e.g. soybean oil, rapeseed oil, etc., and 0.1-40wt% protein, e.g. sodium caseinate, albumin, etc., heated at >=80 deg.C are added and blended with the above-mentioned dispersion and homogenized under a high pressure to provide the aimed emulsion. The use of the fat or oil provides a dispersion of low viscosity and addition of the protein affords the stable emulsion.
Among women who applied to Maternity Hospital 350 pregnant women were assigned to massage group. Participants in massage group filled out an information form including socio-demographic characteristics. Perineum massage with olive oil in the second period of delivery was performed to massage group.In massage group when they progressed to full dilatation of the cervix, the midwife inserted two fingers inside vagina and using a sweeping motion gently stretched the perineum with lubricant 5 up to 10 minutes, in and between mother's pushing in the second stage of labour.
Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
Whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
Sarcopenia has a complex pathophysiology that encompasses metabolic dysregulation and muscle ultrastructural changes. Among the drivers of intracellular and ultrastructural changes of muscle fibers in sarcopenia, mitochondria and their quality control pathways play relevant roles. Mononucleated muscle stem cells/satellite cells (MSCs) have been attributed a critical role in muscle repair after an injury. The involvement of mitochondria in supporting MSC-directed muscle repair is unclear. There is evidence that a reduction in mitochondrial biogenesis blunts muscle repair, thus indicating that the delivery of functional mitochondria to injured muscles can be harnessed to limit muscle fibrosis and enhance restoration of muscle function. Injection of autologous respiration-competent mitochondria from uninjured sites to damaged tissue has been shown to reduce infarct size and enhance cell survival in preclinical models of ischemia-reperfusion. Furthermore, the incorporation of donor mitochondria into MSCs enhances lung and cardiac tissue repair. This strategy has also been tested for regeneration purposes in traumatic muscle injuries. Indeed, the systemic delivery of mitochondria promotes muscle regeneration and restores muscle mass and function while reducing fibrosis during recovery after an injury. In this review, we discuss the contribution of altered MSC function to sarcopenia and illustrate the prospect of harnessing mitochondrial delivery and restoration of MSCs as a therapeutic strategy against age-related sarcopenia.
Breast cancer (BC) stands out as the most commonly type of cancer diagnosed in women worldwide, and chemotherapy, a key component of treatment, exacerbates cancer-induced skeletal muscle wasting, contributing to adverse health outcomes. Notably, the impact of chemotherapy on skeletal muscle seems to surpass that of the cancer itself, with inflammation identified as a common trigger for muscle wasting in both contexts. In skeletal muscle, pro-inflammatory cytokines modulate pathways crucial for the delicate balance between protein synthesis and breakdown, as well as satellite cell activation and myonuclear accretion. Physical exercise consistently emerges as a crucial therapeutic strategy to counteract cancer and chemotherapy-induced muscle wasting, ultimately enhancing patients' quality of life. However, a "one size fits all" approach does not apply to the prescription of exercise for BC patients, with factors such as age, menopause and comorbidities influencing the response to exercise. Hence, tailored exercise regimens, considering factors such as duration, frequency, intensity, and type, are essential to maximize efficacy in mitigating muscle wasting and improving disease outcomes. Despite the well-established anti-inflammatory role of aerobic exercise, resistance exercise proves equally or more beneficial in terms of mass and strength gain, as well as enhancing quality of life. This review comprehensively explores the molecular pathways affected by distinct exercise regimens in the skeletal muscle of cancer patients during chemotherapy, providing critical insights for precise exercise implementation to prevent skeletal muscle wasting.
Systems and method are provided for generating a record of a medical procedure. A system includes a processor and a non-transitory computer readable medium. The medium includes a graphical user interface configured to display a graphic representing an anatomical region of a patient and accept a gesture from a user comprising a selected procedure and, diagnosis when appropriate, and a location on the displayed anatomical region. A knowledge base stores a plurality of templates, each comprising a set of fields. A record generation engine selects an associated one of the plurality of templates according to each of the selected procedure and, diagnosis when appropriate, and the location on the displayed anatomical region and populates the set of fields associated with the selected template. A database interface formats the populated template into a database record suitable for an electronic health records database associated with the system.
PURPOSE: A composition containing variuos novel uracil derivative compounds is provided to prevent or treat neuropathic pain, autoimmune diseases, or degenerative diseases. CONSTITUTION: A uracil derivative is denoted by chemical formula 1. Heteroaryl is quinoline or isoquinoline. A composition for preventing or treating chronic inflammatory diseases, inflammatory diseases, or neuropathic pain contains the uracil derivative as an active ingredient. A composition for preventing or treating autoimmune diseases contains the uracil derivative as an active ingredient. A composition for preventing or treating degenerative diseases contains the uracil derivative as an active ingredient.
The anemic pregnant women in the study group received an integrated health education in one session. The educational session was steered as 40-minutes session in a personalized manner. The educational session content included; disease specific information, effect of anemia on maternal and neonatal outcome, management possibilities, the effectiveness, benefits and disadvantages of treatment options, identify diet rich with iron, false dietary habits prevent iron absorption and the balanced diet and meals.
Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
The Autoimmune Lymphoproliferative Syndrome (ALPS) is an inherited disease associated with a defect of lymphocyte apoptosis that leads to lymphoproliferation and autoimmunity. Although, there are treatments for many of its complications, there currently is no safe and effective therapy for this syndrome itself. Recently investigators in Europe serendipitously observed that some children with ALPS showed reductions in spleen and lymph node size while in pyrimethamine/sulfadoxine (Fansidar) for Pneumocystis carinii prophylaxis. Our own subsequent pilot clinical trial of Fansidar (Protocol #01-I-0132) was terminated after failure to recruit well-defined ALPS patients who lacked histories suspicious for allergies to sulfa drugs. Our own in vitro studies, however revealed that pyrimethamine and not sulfadoxine induces lymphocyte apoptosis and this observation has suggested to us that pyrimethamine may be beneficial alone, thus avoiding the added risks of allergy and hypersensitivity associated with the sulfa drugs. However, potential bone marrow toxicity that may result from an escalating dose schedule of pyrimethamine should respond to the addition of folinic acid (Leucovorin) to the regimen.

We propose to conduct a pilot study on the safety and efficacy of the drug, pyrimethamine for the treatment of ALPS. Six to 8 individuals, with ALPS will be treated for up to 3 months, initially, with twice-weekly pyrimethamine (Daraprim) at escalating doses adjusted by weight, with the addition of folinic acid when needed to aid management of marrow toxicity. The effects of pyrimethamine treatment on lymph node and/or spleen size will be assessed by CT scan. The effect of treatment on other laboratory features of ALPS will also be assessed. Evaluating the effects of pyrimethamine on these clinical and laboratory parameters will allow us to determine if this drug demonstrates sufficient activity to warrant study in a larger randomized controlled trial.
Endometrial cancer is in third place among cancer diseases in female population of Russia. The peak morbidity occurs during the postmenopausal period. In this regard, early diagnosis of previous endometrial proliferative processes and effective methods for their treatment are relevant. However, failures with hormonal therapy are often observed. This may be due to the low receptivity of the pathological tissue. It is also known that the functional activity of immunocompetent cells is controlled by the immune system, however, studies of the receptivity of peripheral blood mononuclear cells to sex steroid hormones were carried out in healthy blood donors. Changes in mononuclear cells receptivity may be one of the pathogenetic links in the development of endometrial proliferative processes and endometrial cancer. This may also influence the effectiveness of their treatment. In this regard, the purpose of the study is to evaluate the role of the expression of estradiol and progesterone receptor genes in endometrial tissue and peripheral blood mononuclear cells in the occurrence of endometrial proliferative processes in postmenopausal patients with a pathogenetic justification for the choice of treatment method. To achieve this goal, the investigators investigated the expression level of estrogen and progesterone receptors (ERa, ERb, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene. The data obtained made it possible to determine the significance of mononuclear cell receptivity in the pathogenesis of endometrial proliferative processes.
STATEMENT OF PROBLEM: Temporomandibular disorders (TMDs) affect the muscles of mastication, the temporomandibular joint, and associated structures. They are generally classified as muscular or articular and are the main cause of pain in the orofacial region, eventually causing psychological problems. However, the real burden of psychological disorders is unknown.
PURPOSE: The purpose of this systematic review and meta-analysis was to assess the prevalence of psychological disorders in patients with TMDs.
MATERIAL AND METHODS: The study was conducted through a bibliographic search carried out without initial limit until July 2021 in the following electronic databases: MEDLINE/PubMed, Scopus, and PsycINFO. Clinical observational studies investigating depression and somatization in patients with TMD diagnosed by the Diagnostic Research for Temporomandibular Disorders (RDC/TMD) criteria in muscular, articular, and disc disorders were included. A descriptive analysis of the included studies and a meta-analysis for the prevalence data were performed for the synthesis of evidence.
RESULTS: A total of 2320 studies were found, of which 48 complete articles were assessed for eligibility and 22 were included in the analysis. The general prevalence of depression and moderate and severe somatization in patients diagnosed with TMD was estimated at 43.0% (95% confidence interval (CI), 36.0% to 50.0%) and 60.0% (95% CI 52.0 - 67, 0%). The average overall score for depression was estimated at 0.92 (95% CI, 0.69-1.15), being classified as moderate depression. The average overall score for somatization was estimated at 1.09 (95% CI, 0.81-1.36), being classified as severe somatization. All analyses showed high heterogeneity (I2>90%). Based on the quality assessment, 80.9% of studies included in the review had low to moderate risk of bias.
CONCLUSIONS: Patients with TMDs who seek clinical care show a high prevalence of depression and somatization.
Spinal circuitries below a paralyzing injury have a functional potential that far exceeds what has been thought possible. It has been demonstrated that task-specific motor therapy combined with epidural spinal cord stimulation (ESS) can promote improved motor function during postural, locomotor, and voluntary movement tasks, resulting in dramatic effects on the wellbeing of individuals with spinal cord injury (SCI). While these findings indicate a substantial promise for restoring mobility even after motor complete paralysis, chronic ESS is based on a high-cost implantable device, as well as an expensive and invasive surgical procedure. The investigators have developed a cost-effective alternative to ESS - non-invasive, transcutaneous electrical stimulation of the spinal cord (TSS). Preliminary works demonstrate that this neuromodulatory strategy provides sufficient specificity to selectively stimulate multisegmental dorsal nerve roots, enable stepping movements, and improve postural control during sitting and standing in individuals with motor complete SCI. The similarities between the effects of ESS and TSS are of critical importance in guiding more individually-specific neuromodulatory approaches to improve motor function and mobility after SCI, but have not been compared directly in the same subjects.

This study is focused on investigation the effects and mechanisms of each spinal neuromodulation strategy in regaining self-assisted standing. Not only is the recovery of balance control one of the most desired goals of people with paralysis, it provides the foundation necessary for regaining the ability to walk, and is critical to future therapies, involving robotic (e.g. exoskeleton) technologies. The objectives of this study are (1) to define the therapeutic potential of TSS during standing in individuals with motor complete SCI, and (2) to identify the neurophysiological and functional signatures of TSS and ESS. The central hypothesis is that each of the neuromodulatory strategies, when individually tailored, can result in significant motor recovery in individuals with chronic paralysis by reactivation and integration of networks that were clinically dormant prior to the intervention. The investigators predict that this proposal will have a high impact given that it encompasses multiple functional systems that contribute to the independence and quality of life in a broad population of individuals with SCI, and provides the first direct comparison of the invasive and non-invasive approaches. The investigators propose a progressive, mechanistic, and translational study to validate the effects of each approach, examine the neuroplastic capacity caused by activity-based training in the presence of TSS, and evaluate TSS and ESS stimulation paradigms as rehabilitative modalities after SCI.